Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$20.09 USD
-0.26 (-1.28%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $20.10 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
TYRA 20.09 -0.26(-1.28%)
Will TYRA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TYRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TYRA
Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
TYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
Other News for TYRA
Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
Analysts Conflicted on These Healthcare Names: Tyra Bioscience (TYRA), Spruce Biosciences (SPRB) and UnitedHealth (UNH)
Tyra Biosciences to Present at Upcoming Investor Conferences
Buy Rating Affirmed: TYRA-300’s Progress and Potent FGFR3 Inhibition Signal Promising Outcomes for Tyra Bioscience